Streetbeat News

Stock Prices

PIII

P3 Health Partners (NASDAQ:PIII) reported Q4 earnings with an EPS of $-0.22, missing estimates by -100.0% against an expected $-0.11. Revenue increased by $88.66 million from the same period last year. Despite missing this quarter's earnings estimate, the company had previously beaten EPS estimates in Q3 2023, which led to a 6.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:45 pm

AREC

American Res (NASDAQ:AREC) reported Q4 earnings with an EPS of $-0.15, missing estimates by -275.0% against an expected $-0.04. Revenue decreased by $4.62 million from the previous year. Despite a positive performance in the previous quarter leading to a 31.0% share price increase, this quarter's results were disappointing.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:45 pm

WATT

Energous (NASDAQ:WATT) reported Q4 earnings with a loss of $(0.74) per share, surpassing the $(0.85) estimate, marking a 47.14% improvement year-over-year. However, their sales of $91.67K fell short of the $200.00K estimate, a 48.84% decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:38 pm

MNST

Over the past 10 years, Monster Beverage (NASDAQ:MNST) has outperformed the market with an average annual return of 17.71%, turning a $100 investment into $500.61. The company now has a market capitalization of $62.00 billion.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:30 pm

ACGL

Arch Capital Group (NASDAQ:ACGL) has delivered an average annual return of 16.03% over the past 20 years, turning a $1000 investment into $19,365.92 today. The company's market capitalization stands at $34.59 billion.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:30 pm

RKDA

Arcadia Biosciences (NASDAQ:RKDA) reported Q4 earnings with an EPS of $-2.1, beating estimates by 19.0% against an expected $-2.58. Revenue increased by $170 thousand from the same period last year. Despite beating EPS estimates last quarter, RKDA's share price dropped by 3.0% the following day. The company's past earnings performance shows a mixed trend with both beats and misses on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:30 pm

RKDA

Arcadia Biosciences reported Q4 earnings with a loss of $2.10 per share, surpassing the expected $2.58 loss, marking a 66.72% improvement from last year. However, their sales of $1.17M fell short of the $1.75M forecast, despite being a 17% increase from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:27 pm

CPTN

Cepton (NASDAQ:CPTN) reported Q4 earnings with an EPS of $-0.41, beating estimates by 45.0% against an expected $-0.74. Revenue increased by $3.38 million from the same period last year. Despite beating EPS estimates in the past, such as last quarter's beat by $0.34, Cepton's share price dropped by 5.0% the following day. The company has shown a pattern of surpassing EPS estimates but faces volatility in share price post-earnings announcement.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:20 pm

AXDX

Accelerate Diagnostics (NASDAQ:AXDX) reported Q4 earnings with a loss of $(0.89) per share, missing the $(0.62) estimate, and sales of $3.03M, below the $3.45M estimate. This represents a 493.33% increase in losses and a 1.85% increase in sales year-over-year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:13 pm

DLPN

Dolphin Entertainment (NASDAQ:DLPN) reported a significant increase in quarterly losses to $(0.54) per share from $(0.21) YoY, despite beating sales estimates with $12.00M against the expected $11.10M. This represents a 157.14% increase in losses and a 7.73% increase in sales compared to the same period last year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:06 pm